BIOLINERX LTD/S (BLRX) to Release Quarterly Earnings on Thursday

Share on StockTwits

BIOLINERX LTD/S (NASDAQ:BLRX) will be releasing its earnings data before the market opens on Thursday, March 28th.

NASDAQ:BLRX opened at $0.44 on Tuesday. The company has a market capitalization of $46.00 million, a PE ratio of -1.63 and a beta of 1.70. BIOLINERX LTD/S has a 1-year low of $0.38 and a 1-year high of $1.84.

A number of research firms have recently weighed in on BLRX. Oppenheimer set a $3.00 price objective on shares of BIOLINERX LTD/S and gave the company a “buy” rating in a research report on Wednesday, December 12th. HC Wainwright set a $4.00 price target on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Tuesday, December 11th. Finally, Maxim Group set a $2.00 price target on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Wednesday, December 12th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $2.50.

COPYRIGHT VIOLATION WARNING: “BIOLINERX LTD/S (BLRX) to Release Quarterly Earnings on Thursday” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/4248781/biolinerx-ltd-s-blrx-to-release-quarterly-earnings-on-thursday.html.

BIOLINERX LTD/S Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

See Also: How does a 12b-1 fee affect fund performance?

Earnings History for BIOLINERX LTD/S (NASDAQ:BLRX)

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

PeepCoin Price Up 10.7% This Week
PeepCoin Price Up 10.7% This Week
Reston Wealth Management LLC Acquires New Position in SPDR S&P 600 Small CapETF
Reston Wealth Management LLC Acquires New Position in SPDR S&P 600 Small CapETF
Cray  Shares Up 5.1%
Cray Shares Up 5.1%
TAP Consulting LLC Acquires Shares of 1,638 iShares S&P Mid-Cap 400 Value ETF
TAP Consulting LLC Acquires Shares of 1,638 iShares S&P Mid-Cap 400 Value ETF
14,914 Shares in Schwab International Small-Cap Equity ETF  Acquired by Stokes Capital Advisors LLC
14,914 Shares in Schwab International Small-Cap Equity ETF Acquired by Stokes Capital Advisors LLC
Lesa Sroufe & Co Sells 8,910 Shares of Schnitzer Steel Industries, Inc.
Lesa Sroufe & Co Sells 8,910 Shares of Schnitzer Steel Industries, Inc.


© 2006-2019 Ticker Report